| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Annexin Pharmaceuticals AB: First patient treated with vanexin following anti-VEGF injection in the NEXUS study | 213 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces that the first patient in the expanded patient cohort of the NEXUS study has now been treated according to the new study design. The patient, diagnosed with retinal... ► Artikel lesen | |
| 21.08. | Annexin Pharmaceuticals AB: Annexin advances the NEXUS study to include patients who received an anti-VEGF injection | 256 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces a next patient cohort in the NEXUS study. The company continues to study the effects of the drug candidate vanexin (formerly ANXV) in patients with retinal vein... ► Artikel lesen | |
| 20.08. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV | 318 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for the company's drug candidate ANXV.... ► Artikel lesen | |
| ANNEXIN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 21.07. | Annexin Pharmaceuticals AB: Annexin updates on nine patients treated in NEXUS study | 274 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the patient recruitment status in the NEXUS study. As of today, six patients with retinal vein occlusion (RVO) and three patients with diabetic retinopathy... ► Artikel lesen | |
| 03.07. | Annexin Pharmaceuticals AB: Annexin's rights issue 98 percent subscribed | 336 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 23.06. | Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO | 341 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been associated with limiting safety or tolerability... ► Artikel lesen | |
| 15.06. | Annexin Pharmaceuticals AB: The subscription period in Annexin Pharmaceuticals' rights issue begins today | 292 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 12.06. | Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB | 426 | GlobeNewswire | With effect from June 15, 2026, the subscription rights in Annexin Pharmaceuticals AB will be traded on First North Growth Market. Trading will continue up until and including June 29, 2026.
... ► Artikel lesen | |
| 10.06. | Annexin Pharmaceuticals AB: Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue | 267 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 09.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.06.2026 | 1.180 | Xetra Newsboard | Das Instrument G85 CA35958L1013 FUERTE METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 09.06.2026 und ex Kapitalmassnahme am 10.06.2026 The instrument G85 CA35958L1013 FUERTE METALS CORP.... ► Artikel lesen | |
| 03.06. | Annexin Pharmaceuticals AB: Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million | 317 | GlobeNewswire (Europe) | NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW... ► Artikel lesen | |
| 21.05. | Annexin Pharmaceuticals AB: Annexin investigates a three-day ANXV treatment regimen in patients with RVO | 333 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces a shortening of the ANXV treatment regimen from five to three days at the same dose level. A three-day treatment is expected to strengthen the commercial value... ► Artikel lesen | |
| 11.05. | Annexin Pharmaceuticals AB: Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study | 334 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the company has received an approval for a clinical trial with the drug candidate ANXV by the German Medicines Agency Bundesinstitut für Arzneimittel... ► Artikel lesen | |
| 22.04. | Annexin Pharmaceuticals AB: Annexin accelerates patient recruitment - five patients treated | 394 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces an update on patient recruitment in the ongoing Phase 2a/Proof of Concept study NEXUS, investigating the drug candidate ANXV in retinal vein occlusion (RVO)... ► Artikel lesen | |
| 13.04. | Annexin Pharmaceuticals AB: Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026 | 319 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB (publ) today announces that the company has secured bridge financing of approximately SEK 4 million and intends to carry out a rights issue of approximately SEK 20 million... ► Artikel lesen | |
| 04.02. | Annexin Pharmaceuticals AB: Favourable findings in Annexin's ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion | 771 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces favourable findings in the company's ongoing Proof of Concept Phase 2a study with the drug candidate ANXV in Diabetic Retinopathy (DR) and Retinal Vein Occlusion... ► Artikel lesen | |
| 05.12.25 | Annexin Pharmaceuticals AB: First patients treated in Annexin's Phase 2a study in diabetic retinopathy and RVO | 391 | GlobeNewswire (Europe) | Annexin Pharmaceuticals AB today announces that the first two patients have been dosed in the company's Proof of Concept Phase 2a study with the drug candidate ANXV in diabetic retinopathy (DR) and... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 81,90 | +2,38 % | Guggenheim raises CG Oncology stock price target on trial results | ||
| SUMMIT THERAPEUTICS | 10,570 | +0,67 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| QIAGEN | 45,250 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,340 | -1,62 % | ADMA Biologics (NDQ:ADMA): The Antibody Factory, The Short Seller Attack, And The Earnings That Followed | ||
| ARCUTIS BIOTHERAPEUTICS | 27,170 | -1,59 % | Arcutis Biotherapeutics legt Studiendaten zu Neurodermitis-Behandlung bei Säuglingen vor | ||
| PRAXIS PRECISION MEDICINES | 310,72 | +1,86 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| RECURSION PHARMACEUTICALS | 2,725 | +0,18 % | Recursion CEO details novel Phase III endpoint for rare disease drug | ||
| MBX BIOSCIENCES | 53,41 | -0,02 % | Citizens reiterates MBX Biosciences stock rating on GLP agonist data | ||
| TREVI THERAPEUTICS | 13,720 | +1,55 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| IMMUNOVANT | 32,520 | -1,96 % | Immunovant Inc - IMVT: Gap Up & Pullback nach den Earnings! | Wirkstoffkandidat IMVT-1402 Rücksetzer zum 20er-EMA. Immunovant-Aktie (IMVT) für spekulativen Biotech-Daytrade? Klinische Studien und Marktzulassungen fehlen noch! Immunovant (IMVT) - ISIN US45258J1025... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,410 | +3,39 % | Enliven Therapeutics auf der Jefferies-Konferenz: Fokus auf CML-Pivotalstudie und solide Liquidität | ||
| ERASCA | 14,230 | +3,27 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,920 | -0,43 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| MAZE THERAPEUTICS | 32,400 | 0,00 % | Maze Therapeutics auf der Jefferies Global Healthcare Conference: Pipeline-Fortschritte und finanzielle Reichweite bis 2029 | ||
| KYMERA THERAPEUTICS | 119,48 | -1,68 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen |